Recently, Randox Laboratories have developed a multiplex test (Prostate Cancer Risk Biochip) which can simultaneously measure the levels of IL-8, EGF, MCP-1 and tPSA from a single serum sample. The gene discussed is CCL2; the disease is prostate carcinoma.